Patient advocacy news // 24th February 2020
This year looks set to be a busy year for our patient advocacy team with at least six Health Technology Assessments (HTA) expected for three new myeloma treatments. Three of the appraisals will be considered by the National Institute for Health and Care Excellence (NICE) and three by the Scottish Medicines Consortium (SMC).
Isatuximab, pomalidomide (Imnovid®) and dexamethasone
The combination of isatuximab, pomalidomide and dexamethasone is currently being considered for myeloma patients who have received at least three previous lines of treatment including lenalidomide and a proteasome inhibitor (bortezomib (Velcade®), carfilzomib (Kyprolis®) or ixazomib (Ninlaro®)).
Myeloma UK submitted evidence for the appraisal in November 2019. The NICE committee meeting to discuss and review the clinical and cost-effectiveness is scheduled for the 13 May 2020, with the final decision expected on the 5 August 2020. The final positioning of this treatment will be determined as part of the appraisal.
Although dates have not been confirmed we anticipate that this combination will also be assessed by the SMC in 2020
This treatment is currently available to some myeloma patients through the Early Access to Medicines Scheme (EAMS) until the treatment is granted a licence by the European Medicines Agency (EMA).
Carfilzomib (Kryprolis®), lenalidomide (Revlimid®) and dexamethasone
The combination of carfilzomib, lenalidomide and dexamethasone is being considered for patients who have received at least one previous treatment. This appraisal follows a review by NICE of its earlier decision not to approve the treatment. Myeloma UK submitted evidence in January 2020 and the proposed date for the committee meeting is the 7 of July 2020. Publication of the final advice will follow in October 2020. The final positioning of this treatment will be determined as part of the appraisal.
Although dates have not been confirmed we anticipate that this combination will also be assessed by the SMC in 2020.
Lenalidomide maintenance is currently being assessed for the treatment of newly diagnosed patients following high-dose therapy and stem cell transplantation (HDT-SCT). Many patients in the UK will have taken part in the Myeloma XI clinical trial for lenalidomide maintenance and we have been expecting this HTA for some time.
We submitted evidence for the NICE appraisal of lenalidomide maintenance in February 2020. To help support our evidence submission, Myeloma UK conducted a patient treatment survey asking for patients’ views on lenalidomide maintenance. There has been a fantastic response to this survey, 466 responses, which formed part of our evidence submission. NICE has indicated that the earliest a final decision can be expected on this appraisal is October 2020.
Although dates have not been confirmed we anticipate that this treatment will also be assessed by the SMC in 2020.
The active HTA schedule is a welcome sign of the continuing advances in treatment in myeloma. We will continue to work with patients, their families and carers, and with clinicians to make the case for the approval of effective new myeloma treatments. We will also continue to update patients and healthcare professionals on the progress of these HTAs.
If you would like some more information on any of new treatments or HTA processes then please do get in touch at firstname.lastname@example.org.